Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity

Journal of Immunology

Volumn 182, Issue 10, 2009, Pages 6095-6104

  Lin, Yung Chang ^a,c   Chang, Li Yuan ^b   Huang, Ching Tai ^a,c   Peng, Hui Min ^c   Dutta, Avijit ^c   Chen, Tse Ching ^a,c   Yeh, Chau Ting ^a,c   Lin, Chun Yen ^a,b,c  

^a University College of Medicine   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CHEMOKINE RECEPTOR; GRANZYME B; PERFORIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MOLECULE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; IMMUNOLOGIC MEMORY; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 77952376596     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803829     Document Type: Article

References (50)

1. Ehrlich, P. 1906. Collected Studies on Immunity. J. Wiley & Sons. London, U.K.
2. Bashford, E., J. Murray, and M. Haaland. 1908. Resistance and susceptibility to inoculated cancer. In Third Scientific Report on the Investigations of the Imperial Cancer Research Fund. E. Bashford, ed. Taylor & Francis, London, U.K., p. 359.
3. Berendt, M. J., R. J. North, and D. P. Kirstein. 1978. The immunological basis of endotoxin-induced tumor regression: requirement for a pre-existing state of concomitant antitumor immunity. J. Exp. Med. 148: 1560-1569. (Pubitemid 9084031)
4. Deckers, P. J., B. W. Edgerton, B. S. Thomas, and Y. H. Pilch. 1971. The adoptive transfer of concomitant immunity to murine tumor isografts with spleen cells from tumor-bearing animals. Cancer Res. 31: 734-742.
5. Howell, S. B., J. H. Dean, and L. W. Law. 1975. Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int. J. Cancer 15: 152-169.
6. Zarling, J. M., and S. S. Tevethia. 1973. Transplantation immunity major persistence and immunity. Nature 420: 502-507.
7. North, R. J., and I. Bursuker. 1984. Generation and decay of the immune response to a progressive fibrosarcoma: I. Ly-12-suppressor T cells down-regulate the generation of Ly-1-2 effector T cells. J. Exp. Med. 159: 1295-1311.
8. DiGiacomo, A., and R. J. North. 1986. T cell suppressors of antitumor immunity: the production of Ly-1-,2 suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J. Exp. Med. 164: 1179-1192. (Pubitemid 16031615)
9. Turk, M. J., J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
10. Curiel, T. J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117: 1167-1174.
11. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, E. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
12. Bates, G. J., S. B. Fox, C. Han, R. D. Leek, J. F. Garcia, A. L. Harris, and A. H. Banham. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24: 5373-5380.
13. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13: 902-911.
14. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
15. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25: 207-217.
16. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61: 8643-8646.
17. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
18. Chen, M. L., M. J. Pittet, L. Gorelik, R. A. Flavell, R. Weissleder, H. von Boehmer, and K. Khazaie. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl. Acad. Sci. USA 102: 419-424.
19. + helper T cell responses in cancer patients. Blood 106: 1008-1011.
20. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400.
21. + regulatory T cells participate in the control of immune responses. J. Immunol. 178: 6901-6911.
22. + regulatory T cells. J. Exp. Med. 199: 303-313.
23. Liyanage, U. K., T. T. Moore, H.-G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
24. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538-18543.
25. Mantovani, A., P. Romero, A. K. Palucka, and F. M. Marincola. 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
26. Borrello, M. G., L. Alberti, A. Fischer, D. D. Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, et al. 2005. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. USA 102: 14825-14830.
27. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
28. + regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 112: 2129-2138.
29. Cavassani, K. A., A. P. Campanelli, A. P. Moreira, J. O. Vancim, L. H. Vitali, R. C. Mamede, R. Martinez, and J. S. Silva. 2006. Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J. Immunol. 177: 5811-5818.
30. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332.
31. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321. (Pubitemid 16002234)
32. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319: 1676-1680.
33. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4: 525-531.
34. Frey, A. B., and N. Monu. 2006. Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J. Leukocyte Biol. 79: 652-662.
35. + Tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J. Immunol. 166: 6074-6083.
36. + Tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 167: 5042-5051.
37. Zou, W. 2005. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
38. Pardoll, D. M. 2001. Immunology, stress, NK receptors, and immune surveillance. Science 294: 534-536.
39. van Elsas, A., R. P. M. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J.-P. Medema, W. W. Overwijk, N. P. Restifo, C. J. M. Melief, R. Offringa, and J. P. Allison. 2001. Elucidating the autoimmune and antitumour effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194: 481-489.
40. + cells unmasks tumour immunogenicity leading to the rejection of late-stage tumours. J. Exp. Med. 201: 779-791.
41. + Treg and control of Leishmania major infection. J. Immunol. 174: 5444-5455.
42. Lin, C. Y., M. C. Tsai, C. T. Huang, C. W. Hsu, S. C. Tseng, I. F. Tsai, Y. C. Chen, C. T. Yeh, I. S. Sheen, and R. N. Chien. 2007. Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. J. Viral. Hepatol. 14: 503-511.
43. Annacker, O., J. L. Coombes, V. Malmstrom, H. H. Uhlig, T. Bourne, B. Johansson-Lindbom, W. W. Agace, C. M. Parker, and F. Powrie. 2005. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J. Exp. Med. 202: 1051-1061.
44. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244.
45. Cerf-Bensussan, A. Jarry, N. Brousse, B. Lisowska-Grospierre, D. Guy-Grand, and C. Griscelli. 1987. A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur. J. Immunol. 17: 1279-1285.
46. + regulatory T cells results in tissue-specific inflammatory disease. J. Exp. Med. 204: 1335-1347.
47. + T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med. 201: 1037-1044.
48. + regulatory T cells during acute graft-versus-host disease. Blood 106: 3300-3307.
49. + regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203: 2451-2460.
50. Cao, X., S. Cai, T. Fehniger, J. Song, L. Collins, D. Piwnica-Worms, and T. Ley. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646. (Pubitemid 47628832)